Related Experiment Video
Updated: Feb 2, 2026
Author Spotlight: Development of a Method for Identifying Small Molecular Antagonists of β2 Integrin Activation
Published on: February 2, 2024
Integrins as A New Target for Cancer Treatment
Izabela Łasiñska1, Jacek Mackiewicz1,2,3
1Department of Medical and Experimental Oncology, Heliodor Swiecicki University Hospital, Poznan University of Medical Sciences, Poznan, Poland.
Abstract:
Despite the great progress in the development of targeted therapies for different types of cancer utilizing monoclonal antibodies (e.g., cetuximab for colorectal cancer and head and neck cancer therapy), kinase inhibitors (e.g., sorafenib for kidney cancer and gastrointestinal stromal tumours therapy), and immunomodulatory treatments (e.g., nivolumab and pembrolizumab for melanoma therapy and lung cancer therapy), there is still a need to search for new, more effective treatments. Integrins are responsible for intercellular adhesion and interaction with the cellular matrix. The function of integrins is related to the transduction of intracellular signals associated with adhesion, migration, cell proliferation, differentiation, and apoptosis. Molecules targeting integrins that lead to cancer cell death have been developed. The most advanced molecules studied in clinical trials are abituzumab, intetumumab and cilengitide. There are different groups of anti-integrin drugs: monoclonal antibodies (e.g., abituzumab) and other such as cilengitide, E7820 and MK-0429. These drugs have been evaluated in various cancer types. However, they have shown modest efficacy, and none of them have yet been approved for cancer treatment. Studies have shown that patient selection using biomarkers might improve the efficacy of anti-integrin cancer treatment. Many preclinical models have demonstrated promising results using integrin visualization for cancer detection and treatment efficacy monitoring; however, these strategies require further evaluation in humans.
Insights
Targeting integrins offers a novel approach to cancer therapy, but current treatments show limited efficacy. Biomarker-guided patient selection and integrin visualization may enhance future anti-integrin cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Targeted cancer therapies like monoclonal antibodies and kinase inhibitors have advanced treatment, yet new strategies are needed.
- Integrins play crucial roles in cell adhesion, migration, proliferation, and apoptosis, making them potential targets for cancer therapy.
- Current anti-integrin drugs, including monoclonal antibodies and small molecules, have demonstrated modest efficacy in clinical trials for various cancers.
Purpose of the Study:
- To review the development and clinical evaluation of anti-integrin drugs for cancer treatment.
- To explore strategies for improving the efficacy of integrin-targeted therapies, such as patient selection and diagnostic imaging.
- To highlight the potential of integrin visualization in cancer detection and treatment monitoring.
Main Methods:
- Review of clinical trial data for anti-integrin agents like abituzumab, intetumumab, and cilengitide.
- Analysis of preclinical studies investigating integrin function and targeting in cancer models.
- Examination of research on biomarker-driven patient selection for targeted cancer therapies.
Main Results:
- Several anti-integrin drugs have been evaluated in clinical trials, but none have achieved regulatory approval due to modest efficacy.
- Preclinical studies show promise for integrin visualization in cancer detection and monitoring treatment response.
- Biomarker-based patient stratification is suggested as a method to improve the effectiveness of anti-integrin therapies.
Conclusions:
- While anti-integrin therapies show promise, their clinical efficacy remains limited, necessitating further research and development.
- Integrin visualization techniques hold potential for improving cancer diagnosis and assessing treatment outcomes.
- Future advancements in anti-integrin cancer treatment may rely on personalized medicine approaches, including biomarker selection and advanced imaging.
Related Concept Videos
01:10Integrins
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
02:18Cancer